ArticlePloS one2020
Rescued chlorhexidine activity by resveratrol against carbapenem-resistant Acinetobacter baumannii via down-regulation of AdeB efflux pump.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Therapeutic significance of surface-exposed virulence factors in Acinetobacter baumannii pathogenicity.Molecular biology reports · 2026Review
- Medicinal Plants: A Promising Therapeutic Approach for Addressing Antimicrobial Resistance.International journal of molecular sciences · 2026Review
- Targeting MCR-3 and membrane biosynthesis: mechanistic insights into pterostilbene-colistin synergy.Microbiology spectrum · 2026Article
- Acinetobacter baumannii-rare virulence factors and pathogenesis: the impact of biofilm associated protein (Bap), outer membrane vesicles, and iron acquisition system.Archives of microbiology · 2025Review
- Susceptibility of Acinetobacter baumannii isolates from different sources to biocides: a matter of biofilm.Antimicrobial resistance and infection control · 2025Article
- Plant Metabolites as Potential Agents That Potentiate or Block Resistance Mechanisms Involving β-Lactamases and Efflux Pumps.International journal of molecular sciences · 2025Review
- The Impact of Plant-Derived Polyphenols on Combating Efflux-Mediated Antibiotic Resistance.International journal of molecular sciences · 2025Review
- tesG expression as a potential clinical biomarker for chronic Pseudomonas aeruginosa pulmonary biofilm infections.BMC medicine · 2025Article
- Eravacycline Treatment for Carbapenem-ResistantInfection and drug resistance · 2025Article
- The Negative Regulatory Role of Transcriptional Regulator H-NS on the Type VI Secretion System inInfection and drug resistance · 2025Article
- Types and Mechanisms of Efflux Pump Systems and the Potential of Efflux Pump Inhibitors in the Restoration of Antimicrobial Susceptibility, with a Special Reference toPathogens (Basel, Switzerland) · 2024Review
- Inhibition of biofilm formation and preformed biofilm inFrontiers in microbiology · 2024Article
- Antibiotic Potentiation Through Phytochemical-Based Efflux Pump Inhibitors to Combat Multidrug Resistance Bacteria.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producingiScience · 2023Article
- Resveratrol as an Inhibitor of the NorA Efflux Pump and Resistance Modulator inAntibiotics (Basel, Switzerland) · 2023Article
- Resveratrol Increases Sensitivity of Clinical Colistin-Resistant Pseudomonas aeruginosa to ColistinMicrobiology spectrum · 2023Article
- Antimicrobial Peptide Cec4 Eradicates Multidrug-ResistantDrug design, development and therapy · 2023Article
- An Explorative Review on Advanced Approaches to Overcome Bacterial Resistance by Curbing Bacterial Biofilm Formation.Infection and drug resistance · 2023Review
- Quaternary Phosphonium Compound Unveiled as a Potent Disinfectant against Highly ResistantACS infectious diseases · 2022Article
- Synergistic antibacterial and anti-biofilm activities of resveratrol and polymyxin B against multidrug-resistant Pseudomonas aeruginosa.The Journal of antibiotics · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to determine the activity and synergistic mechanisms of resveratrol in combination with chlorhexidine against carbapenem-resistant Acinetobacter baumannii clinical isolates. The activity of resveratrol plus antimicrobial agents was determined by checkerboard and time-kill assay against carbapenem-resistant A. baumannii isolated from patients at the King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Overexpression of efflux pumps that mediates chlorhexidine susceptibility was characterized by the ethidium bromide accumulation assay. The effect of resveratrol on the expression of efflux pump genes (adeB, adeJ, adeG abeS, and aceI) and the two-component regulators, adeR and adeS was determined by RT-qPCR. The combination of resveratrol and chlorhexidine resulted in strong synergistic and bactericidal activity against carbapenem-resistant A. baumannii. Up-regulation of adeB and aceI was induced by chlorhexidine. However, the addition of resveratrol increased chlorhexidine susceptibility with increased intracellular accumulation of ethidium bromide in A. baumannii indicating that resveratrol acts as an efflux pump inhibitor. Expression of adeB was significantly reduced in the combination of resveratrol with chlorhexidine indicating that resveratrol inhibits the AdeB efflux pump and restores chlorhexidine effect on A. baumannii. In conclusion, reduced adeB expression in A. baumannii was mediated by resveratrol suggesting that AdeB efflux pump inhibition contributes to the synergistic mechanism of resveratrol with chlorhexidine. Our finding highlights the potential importance of resveratrol in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.